Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2413-2422

  Baoum, Abdulgader ^a   Dhillon, Navneet ^b   Buch, Shilpa ^c   Berkland, Cory ^a,d  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d University of Kansas   (United States)

Author keywords

A549 cells; Gene delivery; PEI; PLG; Polycations

Indexed keywords

LUCIFERASE; NANOPARTICLE; PLASMA PROTEIN; PLASMID DNA; POLYCATION; POLYGLACTIN; SURFACTANT;

ADSORPTION; ARTICLE; CYTOTOXICITY; ENCAPSULATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; MATERIAL COATING; NANOFABRICATION; POLYMERIZATION;

EID: 77951276022     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21994     Document Type: Article

References (51)

1. Jain RA. 2000. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490.
2. Langer R. 1997. Tissue engineering: A new field and its challenges. Pharm Res 14:840-841. (Pubitemid 27326975)
3. Allen TM, Cullis PR. 2004. Drug delivery systems: Entering the mainstream. Science 303:1818.
4. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1-20. (Pubitemid 32144788)
5. Kreuter J. 1994. Colloidal drug delivery systems. edition. New York: M. Dekker. p. vii, 353.
6. Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329-347. (Pubitemid 36297053)
7. Zimmer A, Kreuter J. 1995. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 16:61-73.
8. Labhasetwar V. 1997. Nanoparticles for drug delivery. Pharm News 4:28-31.
9. Vinogradov SV, Bronich TK, Kabanov AV. 2002. Nanosized cationic hydrogels for drug delivery: Preparation, properties and interactions with cells. Adv Drug Deliv Rev 54:135-147.
10. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. 1998. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J Control Release 54:201-211. (Pubitemid 28342699)
11. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283-318.
12. Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr CM, Hoffman M, Maincent P. 1999. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 184: 97-105. (Pubitemid 29308999)
13. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. 2001. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299:775-781.
14. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P. 1996. Stability study of nanoparticles of poly(ecaprolactone), poly(d, l-lactide) and poly(d, l-lactide-co-glycolide). Biomaterials 17:2191-2197.
15. Schachter DM, Kohn J. 2002. A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides. J Control Release 78:143-153. (Pubitemid 34081860)
16. Cohen-Sacks H, Najajreh Y, Tchaikovski V, Gao G, Elazer V, Dahan R, Gati I, Kanaan M, Waltenberger J, Golomb G. 2002. Novel PDGFbR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther 9:607-616. (Pubitemid 35414523)
17. Panyam J, Zhou W, Prabha S, Sahoo SK, Labhasetwar V. 2002. Rapid endo-lysosomal escape of poly (dl-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 16:1217-1226. (Pubitemid 34815409)
18. Grayson ACR, Cima MJ, Langer R. 2005. Size and temperature effects on poly (lactic-co-glycolic acid) degradation and microreservoir device performance. Biomaterials 26:2137-2145. (Pubitemid 39575357)
19. Torchilin VP, Lukyanov AN. 2003. Peptide and protein drug delivery to and into tumors: Challenges and solutions. Drug Discov Today 8:259-266. (Pubitemid 36293499)
20. Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 290:137-144.
21. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. 1996. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res 13:1838-1845. (Pubitemid 27034116)
22. Zauner W, Farrow NA, Haines AMR. 2001. In vitro uptake of polystyrene microspheres: Effect of particle size, cell line and cell density. J Control Release 71:39-51.
23. Müller RH, Wallis KH. 1993. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int J Pharm 89:25-31.
24. Van Oss CJ. 1978. Phagocytosis as a surface phenomenon. Annu Rev Microbiol 32:19-39.
25. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
26. Hinrichs WLJ, Mancenido FA, Sanders NN, Braeckmans K, De Smedt SC, Demeester J, Frijlink HW. 2006. The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm 311:237-244. (Pubitemid 43319225)
27. Moffatt S, Cristiano RJ. 2006. Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer for targeted delivery to human monocyte-derived dendritic cells. Int J Pharm 321:143-154. (Pubitemid 44247413)
28. Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. 1999. Protein encapsulation within poly (ethylene glycol)-coated nanospheres II. Controlled release properties. Journal of biomedical materials research 47(3):388-395. (Pubitemid 129515609)
29. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ. 2005. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm 292:43-52. (Pubitemid 40255787)
30. Zhang Y, Kohler N, Zhang M. 2002. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23:1553-1561. (Pubitemid 34158578)
31. Csaba N, Caamano P, Sanchez A, Dominguez F, Alonso MJ. 2005. PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: New carriers for gene delivery. Biomacromolecules 6:271-278. (Pubitemid 40277024)
32. Illum L, Davis SS. 1984. The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett 167:79-82. (Pubitemid 14198834)
33. Illum SL, Davis SS. 1983. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J Pharm Sci 72:1086-1089.
34. Moghimi SM, Gray TA. 1997. Single dose of IV-injected poloxamine coated long-circulating particle triggers macrophage clearance of subsequent doses in rats. Clin Sci 93:371-379.
35. Pitard B, Bello-Roufai M, Lambert O, Richard P, Desigaux L, Fernandes S, Lanctin C, Pollard H, Zeghal M, Rescan PY. 2004. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 32:e159.
36. Storm G, Belliot SO, Daemen T, Lasic DD. 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31-48.
37. Munier S, Messai I, Delair T, Verrier B, Ataman-Onal Y. 2005. Cationic PLA nanoparticles for DNA delivery: Comparison of three surface polycations for DNA binding, protection and transfection properties. Colloids Surf B Biointerfaces 43:163-173. (Pubitemid 40909837)
38. Ogris M, Steinlein P, Carotta S, Brunner S, Wagner E. 2001. DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS J 3:43-53.
39. Tiyaboonchai W, Woiszwillo J, Middaugh CR. 2003. Formulation and characterization of DNA - polyethylenimine - dextran sulfate nanoparticles. Eur J Pharm Sci 19:191-202. (Pubitemid 36918411)
40. Tiyaboonchai W, Woiszwillo J, Sims RC, Middaugh CR. 2003. Insulin containing polyethylenimine - dextran sulfate nanoparticles. Int J Pharm 255:139-151. (Pubitemid 36369598)
41. Egea MA, Gamisans F, Valero J, Garcia ME, Garcia ML. 1994. Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles. Farmaco 49:211-217. (Pubitemid 24165639)
42. Kamruzzaman Selim KM, Ha YS, Kim SJ, Chang Y, Kim TJ, Ho Lee G, Kang IK. 2007. Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes. Biomaterials 28:710-716. (Pubitemid 44754877)
43. Yin Win K, Feng SS. 2005. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713-2722. (Pubitemid 39600724)
44. Hirosue S, Müller BG, Mulligan RC, Langer R. 2001. Plasmid DNA encapsulation and release from solvent diffusion nanospheres. J Control Release 70:231-242. (Pubitemid 32144807)
45. Fischer D, von Harpe A, Kissel T. 2000: Polyethylenimine: polymer structure influences the physicochemical and biological effects of plasmid/PEI complexes. Biomaterials:195-211.
46. Kircheis R, Blessing T, Brunner S, Wightman L, Wagner E. 2001. Tumor targeting with surface-shielded ligand - polycation DNA complexes. J Control Release 72:165-170. (Pubitemid 32522354)
47. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. 2003. Fundamentals of pulmonary drug delivery. Respir Med 97:382-387.
48. Mellman I. 1996. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12:575-625.
49. Lühmann T, Rimann M, Bittermann AG, Hall H. 2008. Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjug Chem 19:1907-1916.
50. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. 2008. Nano/micro technologies for delivering macromolecular therapeutics using poly(d, l-lactide-co-glycolide) and its derivatives. J Control Release 125:193-209.
51. Wiethoff CM, Middaugh CR. 2003. Barriers to nonviral gene delivery. J Pharm Sci 92:203-217.